

In the Claims

Applicant has submitted a new complete claim set indicating marked up claims with insertions indicated by underlining and deletions indicated by strikeouts or double bracketing.

1. (Currently amended) A method for diagnosing ~~determining regression, progression or onset of~~ cancer, comprising

contacting a biological sample isolated from a patient, who has or is suspected of having the cancer, with a protein or peptide that binds an antibody, wherein the antibody selectively binds a protein or peptide encoded by a nucleic acid molecule selected from the group consisting of SOX2 (SEQ ID NO:3), SOX1 (SEQ ID NO:4), and ZIC2 (SEQ ID NO:5), ~~SOX3 (SEQ ID NO:11), and SOX21 (SEQ ID NO:12), and~~

determining the presence or level of the antibody as an indication that the subject has ~~of regression, progression or onset of~~ the cancer, wherein the cancer is small cell lung cancer.

2. (Original) The method of claim 1, wherein the sample is a body fluid, a body effusion or a tissue.

3. (Original) The method of claim 2, wherein the sample is blood or serum.

4. (Original) The method of claim 1, wherein the protein or peptide that binds the antibody is a detectable protein or peptide.

5. (Original) The method of claim 4, wherein the detectable protein or peptide is labeled with a radioactive label or an enzyme.

6. (Canceled)

7. (Original) The method of claim 1, wherein the nucleic acid molecule is SOX1 (SEQ ID NO:4).

8. (Original) The method of claim 1, wherein the nucleic acid molecule is ZIC2 (SEQ ID NO:5).

9-10. (Canceled)

11. (Currently amended) The method of claim 1, wherein the sample is contacted with a plurality of proteins or peptides that bind antibodies that selectively bind a plurality of proteins or peptides encoded by nucleic acid molecules selected from the group consisting of ~~SOX2 (SEQ ID NO:3)~~, SOX1 (SEQ ID NO:4), and ZIC2 (SEQ ID NO:5), ~~SOX3 (SEQ ID NO:11), and SOX21 (SEQ ID NO:12).~~

12-14. (Canceled)